Navigation Links
DURECT Announces Proposed Public Offering of Common Stock
Date:11/7/2013

CUPERTINO, Calif., Nov. 7, 2013 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion and to meet working capital needs. All of the shares in the offering are to be sold by DURECT.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

Stifel is acting as sole book-running manager for the proposed offering and Janney Montgomery Scott is acting as co-manager.  

Felix Theeuwes, our Chairman and Chief Scientific Officer, has indicated an interest in purchasing shares of our common stock with an aggregate purchase price of up to approximately $1 million in this offering at the public offering price.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective.  A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov.  When available, copies of the preliminary prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2500.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.

NOTE: POSIDUR, SABER®, ORADUR®, TRANSDUR® and ELADUR® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil, ORADUR-Methylphenidate and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

 

 


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
2. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
3. DURECT Announces Changes to its Board of Directors
4. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
5. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
6. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
7. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
8. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
9. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
10. DURECT to Participate in Upcoming Healthcare Conferences
11. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Calif. , May 25, 2016  Zymo ... testing for their new reference materials that help ... from sample collection to analyses. The rapid growth ... demand for researchers to have standard methods to ... being generated. Biases inherently exist at every step ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... ... Blood Pressure products . , High blood pressure affects millions of people ... high blood pressure can lead to heart disease, stroke, kidney disease, and hardening ...
(Date:5/26/2016)... , ... May 26, 2016 , ... HealthPostures, ergonomics designer ... chair , furniture that may support women during pregnancy. Potential benefits of using the ... improved rest and comfort and healthier levels of sitting and standing. , Need for ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie is a great option ... and save. For a limited time only (offer expires May 31, 2016) customers can ... one, by using the promo code "Memorial" at checkout. The more Bunion Booties purchased, ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The 12th ... 6pm to 7.30pm PST at HP in Palo Alto, CA. This Bay Area biotech ... be led by clinical trial experts from the pharmaceutical company Hallux, biopharma Apexigen, Contract ...
(Date:5/25/2016)... Chicago, IL (PRWEB) , ... May 25, 2016 ... ... HealthScape Advisors,” said Steven Young, a Managing Partner at HealthScape Advisors. “Brad brings ... value-based care within the healthcare delivery system accelerates with the implementation of MACRA, ...
Breaking Medicine News(10 mins):